Aileron Therapeutics (ALRN) Scheduled to Post Earnings on Tuesday

Aileron Therapeutics (NASDAQ:ALRN) will release its earnings data after the market closes on Tuesday, August 6th. Analysts expect Aileron Therapeutics to post earnings of ($0.23) per share for the quarter.

Aileron Therapeutics (NASDAQ:ALRN) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). On average, analysts expect Aileron Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of Aileron Therapeutics stock opened at $0.55 on Monday. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.38. Aileron Therapeutics has a 52-week low of $0.44 and a 52-week high of $4.10. The business has a 50 day moving average price of $0.67.

Several equities analysts have commented on the company. Canaccord Genuity lowered their price objective on Aileron Therapeutics to $5.00 and set a “buy” rating for the company in a research report on Tuesday, April 9th. Zacks Investment Research lowered Aileron Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 8th. ValuEngine raised Aileron Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, William Blair reissued an “outperform” rating on shares of Aileron Therapeutics in a research report on Monday, May 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Aileron Therapeutics has a consensus rating of “Buy” and an average price target of $4.33.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Further Reading: Price to Earnings Ratio (PE)

Earnings History for Aileron Therapeutics (NASDAQ:ALRN)

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with's FREE daily email newsletter.